文献速递血栓与止血

日本真实世界数据:先天性TTP患者从血浆治疗转换为重组ADAMTS13治疗

Therapeutic switch from plasma to recombinant ADAMTS13 for patients with congenital TTP from Japanese real-world data.
PubMed 文献 · Blood · 2025-01-01

本研究基于日本真实世界数据,比较了新鲜冰冻血浆(FFP)与重组ADAMTS13(rADAMTS13)在14例先天性血栓性血小板减少性紫癜(cTTP)患者中的疗效与安全性,其中5例为排除于3期试验的终末期肾病患者。rADAMTS13给药后15分钟ADAMTS13活性峰值中位数显著高于FFP,给药1周后活性维持亦优于FFP,且未报告过敏反应。

要点

  • rADAMTS13给药后15分钟ADAMTS13活性峰值中位数为68.4%,显著高于FFP的15.9%(P < .001)。
  • rADAMTS13给药1周后ADAMTS13活性为11.6%,显著高于FFP的5.1%(P < .001)。
  • rADAMTS13给药后患者未报告过敏反应,且单次输注的便利性受到认可。

核心结论

  • 在14例日本cTTP患者(含5例终末期肾病患者)中,rADAMTS13较FFP提供更高的ADAMTS13活性峰值和1周维持水平,且未报告过敏反应,提示rADAMTS13是cTTP患者中FFP的安全有效替代选择。

研究设计与样本

  • 研究比较了FFP与rADAMTS13在14例日本cTTP患者中的疗效与安全性,其中5例为终末期肾病患者且被排除于3期试验之外。

主要发现

  • rADAMTS13给药后15分钟ADAMTS13活性峰值中位数为68.4%,FFP为15.9%(P < .001)。
  • rADAMTS13给药1周后ADAMTS13活性为11.6%,FFP为5.1%(P < .001)。
  • rADAMTS13给药后患者未报告过敏反应,并认可单次输注的便利性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Congenital thrombotic thrombocytopenic purpura (cTTP) is an ultrarare disorder characterized by thrombocytopenia, microangiopathic hemolytic anemia, and ischemic organ damage caused by pathogenic ADAMTS13 (a disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13) variants. ADAMTS13-containing product, including fresh-frozen plasma (FFP), and plasma-derived factor VIII concentrates are commonly used to supply ADAMTS13; however, frequent hospital visits and allergic reactions are major drawbacks. A recombinant ADAMTS13 (rADAMTS13) was recently developed to address these issues. However, real-world evidence has not been reported owing to the rarity of this condition. This study compared the efficacy and safety of FFP and rADAMTS13 in 14 Japanese patients, including 5 patients with end-stage renal disease who were excluded from the phase 3 trial. The median peak level of ADAMTS13 activity 15 minutes after rADAMTS13 administration was significantly higher than that after FFP (68.4% vs 15.9%; P < .001). ADAMTS13 activity 1 week after rADAMTS13 administration was well maintained compared with FFP infusion (11.6% vs 5.1%; P < .001). Patients reported no allergic reactions after rADAMTS13 administration and appreciated the convenience of a single infusion of rADAMTS13, suggesting that rADAMTS13 is a safe and effective alternative to FFP in patients with cTTP. To our knowledge, this is the first publication of patients with cTTP who switched FFP to novel rADAMTS13 from Japanese real-world data.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Sakai K, Hamamura A, Yoshimura Y, et al. Therapeutic switch from plasma to recombinant ADAMTS13 for patients with congenital TTP from Japanese real-world data. Blood. 2025. PMID: 40090002. doi:10.1182/blood.2024027516

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。